JUNS
Jupiter Neurosciences, Inc. Common Stock
NASDAQ: JUNS · HEALTHCARE · BIOTECHNOLOGY
$0.38
+5.33% today
Updated 2026-04-30
Market cap
$13.16M
P/E ratio
—
P/S ratio
603.58x
EPS (TTM)
$-0.25
Dividend yield
—
52W range
$0 – $3
Volume
0.1M
Jupiter Neurosciences, Inc. Common Stock (JUNS) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $1.13M | $638037.00 | $233281.00 | $0.00 | $0.00 | $21796.00 |
| Revenue growth (YoY) | — | — | -43.3% | -63.4% | -100.0% | — | — |
| Cost of revenue | — | — | — | — | — | — | $4231.00 |
| Gross profit | — | $1.13M | $638037.00 | $233281.00 | — | — | $17565.00 |
| Gross margin | — | 100.0% | 100.0% | 100.0% | — | — | 80.6% |
| R&D | $685741.00 | $1.64M | $1.45M | $942806.00 | $954793.00 | $492660.00 | $2.09M |
| SG&A | $1.49M | $1.34M | $3.10M | $2.72M | $2.92M | $2.60M | $6.84M |
| Operating income | $-2.18M | $-1.85M | $-3.91M | $-3.43M | $-3.87M | $-3.09M | $-8.91M |
| Operating margin | — | -164.4% | -612.4% | -1471.4% | — | — | -40873.2% |
| EBITDA | $-2.73M | $-1.64M | $-4.09M | $-4.22M | $-4.56M | $-2.19M | $-8.58M |
| EBITDA margin | — | -145.7% | -640.4% | -1807.6% | — | — | -39359.9% |
| EBIT | $-2.18M | $-1.85M | $-3.91M | $-3.43M | $-3.87M | $-3.09M | — |
| Interest expense | $317104.00 | $13535.00 | $113994.00 | $740854.00 | $218705.00 | $248366.00 | $66020.00 |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-3.05M | $-1.65M | $-4.38M | $-4.96M | $-4.78M | $-2.44M | $-8.64M |
| Net income growth (YoY) | — | +45.7% | -164.7% | -13.2% | +3.5% | +49.0% | -254.4% |
| Profit margin | — | -146.9% | -686.4% | -2125.2% | — | — | -39662.8% |